FDA Expands Tzield Use for Children With Type 1 Diabetes
WASHINGTON, D.C. — The U.S. Food and Drug Administration has expanded the approved use of Tzield (teplizumab) to children ages 8 to 17 who have been recently diagnosed with Stage …
FDA Expands Tzield Use for Children With Type 1 Diabetes Read More